Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 272,472 shares of the company's stock after selling 8,659 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Johnson & Johnson were worth $42,337,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Lantz Financial LLC increased its stake in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at $453,000. Horan Securities Inc. lifted its holdings in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after acquiring an additional 90 shares during the period. State of Wyoming boosted its holdings in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC grew its holdings in shares of Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Raymond James Financial decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock traded up $0.17 during midday trading on Monday, hitting $152.58. 9,000,581 shares of the company's stock were exchanged, compared to its average volume of 8,022,908. The company has a market cap of $367.12 billion, a PE ratio of 16.97, a P/E/G ratio of 2.31 and a beta of 0.42. The firm has a 50-day moving average of $153.75 and a two-hundred day moving average of $153.81. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.